Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy
$200 Per Share Buyout Is 75% Premium
Executive Summary
Merck will reduce its dependence on oncology and expand in immunology, adding a Phase III-ready TL1A inhibitor for IBD that could reach the market a few years ahead of losing exclusivity for Keytruda.
You may also be interested in...
The Dealmaking Landscape According To Sanofi
Monika Vnuk, head of Sanofi’s business development, says the best candidates are still commanding very high prices and outside inflammation and immunology, the French drugmaker is on the look-out for clinical rather than very early-stage assets.
Roivant Plots ‘Streamlined’ Phase III As Ulcerative Colitis Data Raise Blockbuster Potential
The company announced data from the Phase IIb TUSCANY-2 trial of RVT-3101, which is in a tight race with PRA023 from Prometheus, which Merck recently acquired for $10.8bn.
The Dealmaking Landscape According to Sanofi
Monika Vnuk, head of Sanofi’s business development, tells Scrip that the best candidates are still commanding very high prices and outside inflammation and immunology, the French drugmaker is on the look-out for clinical rather than very early-stage assets.